Mainstreaming Cell & Gene Therapies
Development, manufacturing, regulation and market access
The cell and gene therapy (CGT) market is rapidly transitioning from ultra-niche cutting-edge science to approved and available therapies that can address previously intractable and often devastating diseases. A rich pipeline of CGTs at various stages of development looks set to maintain that momentum for some time yet.
This in-depth examination of the CGT market covers its current state, practicalities of clinical trials, manufacturing and supply challenges, trial compliance and patient recruitment, long-term commercialisation and market access.